← Leaderboards
Devin E Eckhoff
University Of Alabama At Birmingham
$283,641
Attributed
$850,924
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $679.7K · FY2008–11$1M$750K$500K$250K$0
'08
'09
'10
'11
Funding mix
By agency
NIH$1,530,624 · 2
By mechanism
R41$850,924 · 1
U42$679,700 · 1
Top collaborators
- Kathryn J. Macleod3 shared
- Haval Shirwan3 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Maria B Grant$24,532,308
- Kirby I Bland$6,784,098
- Anupam Agarwal$17,840,868
- Edward E Partridge$43,798,134
- Kurt R Zinn$3,944,617
Others in their field
Top investigators on “Alloantigen”
- Alessandro Sette · La Jolla Institute For Immunology$38,795,721
- Mohamed H Sayegh · University Of Pennsylvania$36,148,430
- Donna L Farber · Scripps Research Institute, The$25,646,764
- Reza Abdi · Brigham And Women'S Hospital$21,062,312
- Allan D. Kirk · Emory University$17,724,560
- Jonathan S Bromberg · University Of Michigan At Ann Arbor$16,870,961
Research focus
AlloantigenAllogenicAnimalsApoptosisApoptoticArchitectureAutoantigensBaseBiotinCd95 AntigensCell MaintenanceCellsCell SurfaceChimeric ProteinsChronicClinicClinical TreatmentClinical TrialsCommercializationCritiquesDiabetes MellitusDiabeticEconomic ImpactAcute
Grant awards (4)
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates$399,912
R41 · FY2011 · DK
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates$47,088
R41 · FY2011 · DK
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates$403,924
R41 · FY2010 · DK
Hormonal Therapy to Increase Islet Recovery/Engraftment From Multiorgan Donors$679,700
U42 · FY2008 · RR · contact PI